查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1989944

肛門癌市場：2026-2032年全球市場預測（依治療方法、最終用戶、治療線、分期、給藥途徑、癌症類型和分銷管道分類）

Anal Cancer Market by Treatment Type, End User, Therapeutic Line, Disease Stage, Administration Mode, Cancer Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肛門癌市場價值將達到 11.3 億美元，到 2026 年將成長到 12 億美元，到 2032 年將達到 17.7 億美元，複合年成長率為 6.59%。

主要市場統計數據
基準年 2025 11.3億美元
預計年份：2026年 12億美元
預測年份 2032 17.7億美元
複合年成長率 (%) 6.59%

清晰權威地指南肛門癌的最新臨床進展、不斷發展的護理路徑以及影響肛門癌診斷和治療的策略重點。

免疫腫瘤學、精準診斷和多方面治療方法的進步，已使肛門癌從相對專業的臨床難題轉變為跨學科研究的重點。近年來，隨著臨床醫生在局部控制和器官保留之間尋求平衡，治療流程也日益複雜，全身性治療選擇也擴展到傳統細胞毒性藥物之外。因此，臨床實踐、臨床研發和醫療政策領域的相關人員需要對影響患者預後和資源分配的治療方法、診斷創新以及醫療服務體系變革進行簡明扼要的概述。

分子診斷、免疫療法整合以及醫療保健服務體系的重新設計如何改變肛門癌的治療途徑和商業策略。

肛門癌的治療格局正在經歷一場變革性的轉變，這主要得益於分子層面的深入研究、治療方法的出現以及以患者為中心的醫療服務模式的重新興起。免疫療法正從一項前景廣闊的研究階段治療方法，逐步應用於特定患者群體，這促使人們重新評估與現有放化療放射線治療相比的治療順序和聯合治療策略。同時，放射治療技術和治療計劃的進步使得劑量傳遞更加精準，從而降低了毒性，促進了器官保留，並影響了轉診模式。

2025 年的收費系統要求供應鏈具備韌性，採購結構進行重組，並採取適應性合約措施，以維持治療和臨床運作的正常進行。

美國於2025年實施的費用調整為肛門癌治療領域的相關人員引入了新的變量，包括供應鏈、醫療設備採購以及依賴進口的藥品。短期內，某些專用設備和試劑進口成本的增加迫使採購團隊和醫院藥局調整其採購政策。因此，採購方盡可能地轉向國內供應商，並加快了與替代供應商的談判。這種情況也凸顯了放射治療組件、診斷試劑盒和腸外給藥等易受跨境物流影響的藥品供應鏈規劃的重要性。

從詳細的細分觀點揭示治療方法、醫療保健環境和交付管道如何影響臨床決策和商業性定位。

細分分析揭示了治療方法方案、臨床環境、治療線、疾病分期、給藥途徑、癌症組織學類型和分銷管道如何為相關人員建立不同的決策路徑。在整體治療方法中，傳統化療仍然是基礎，單藥治療和聯合治療則應用於特定的臨床情境，而同步和序貫放射線治療等聯合治療放射線治療在平衡腫瘤控制和功能預後方面發揮核心作用。手術方案包括腹會陰聯合切除術和局部切除術，具體選擇取決於腫瘤範圍、患者意願和挽救性治療的考慮因素。免疫療法（例如查核點抑制劑和疫苗策略）以及標靶治療（例如 EGFR 抑制劑）正在影響晚期治療策略和臨床試驗設計。

對全球市場肛門癌治療的臨床模式、監管環境和進入因素進行區域比較分析。

區域趨勢正對美洲、歐洲、中東和非洲以及亞太地區的臨床實踐模式、報銷標準和臨床試驗生態系統產生重大影響。在美洲，整合的腫瘤網路和完善的臨床試驗基礎設施正在促進變革性證據的快速應用，並支持複雜的聯合治療。同時，支付方的多樣性要求制定細緻入微的准入策略，以兼顧公共和私人報銷機制。許多醫療機構正在轉向基於價值的討論，這正在改變藥物應用談判和患者管理的優先事項。

臨床中心、診斷技術創新者和商業夥伴之間的合作如何加速肛門癌治療方法的開發和市場化。

這種競爭與合作並存的環境涵蓋了生物製藥創新者、診斷公司、合約研究組織 (CRO) 以及專注於藥物遞送和放射治療計劃的醫療設備製造商。領先的臨床研究人員和學術機構持續透過研究者主導的臨床試驗和多中心試驗來推動實證醫學的產生，這些試驗旨在評估聯合治療、新型免疫療法和基於生物標記的方法。診斷服務提供者正在改進分子診斷和病理工作流程，以更深入地了解腫瘤的生物學特徵，從而支持更具選擇性的患者招募和伴隨診斷策略。

為產業領導者提供切實可行的策略，以協調臨床開發、支付方合作和供應鏈韌性，從而在肛門癌領域取得永續的商業性成功。

業界領導企業可以透過將臨床開發與新的護理標準結合，並投資於能夠展現真實世界療效和價值的數據策略，來增強其競爭優勢。優先進行將生物標記定義的患者群體與治療結果聯繫起來的後期轉化研究，可以簡化臨床實驗，並在市場中脫穎而出。此外，將商業化準備計劃與支付方的證據要求和醫療服務提供者的工作流程考慮相結合，可以減少市場上市的障礙，並支持永續的市場滲透。

我們採用透明、多方面的研究途徑，結合臨床證據評估、專家訪談和相關人員的三角檢驗，得出可操作的策略見解。

本分析的調查方法整合了同行評審的臨床文獻、監管指南、臨床專家訪談以及來自支付方和醫療服務提供者等相關人員的定性信息，從而構建出治療、診斷和交付趨勢的全面圖景。數據三角驗證確保臨床結論是基於檢驗的資訊來源，而與專家的諮詢則提供了關於實踐差異和營運考慮的背景資訊。必要時，對治療路徑和相關利益者獎勵的比較分析揭示了其對產品開發和商業化的實際意義。

整合臨床進展、診斷技術改進和營運準備，將指導肛門癌的策略決策，並改善以患者為中心的治療效果。

總之，肛門癌領域正日益成熟，成為一個複雜的多學科交叉領域，治療創新、診斷技術改進和醫療服務模式不斷發展交織融合，共同影響著患者的治療效果和商業性前景。相關人員必須應對這樣一種環境：免疫療法和標靶治療正逐步融入現有的放射線治療方案，診斷技術助力患者篩選，而區域間醫療實踐的差異則影響著患者的就醫途徑和臨床試驗的設計。成功的專案會預見這些變化，將臨床開發與實際應用相結合，建立能夠引起保險公司和醫療服務提供者共鳴的證據，並確保整個供應鏈和分銷管道擁有穩健的營運體系。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肛門癌市場：依治療方法

  • 化療
  • 聯合治療
    • 放射線治療
    • 序貫放射線治療
  • 免疫療法
    • 查核點抑制劑
    • 疫苗療法
  • 放射線治療
    • 近距離放射治療
    • 體外放射治療
  • 外科手術
    • 腹會陰聯合切除術
    • 局部切除

第9章：肛門癌市場：依最終用戶分類

  • 門診手術中心
  • 診斷檢查室
  • 醫院
  • 腫瘤中心
  • 專科診所

第10章：肛門癌市場：依治療方案分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第11章：肛門癌市場：依分期分類

  • 第三階段
  • 第四階段
  • 第一階段-第二階段

第12章：肛門癌市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 外用

第13章：肛門癌市場：依癌症類型分類

  • 腺癌
  • 惡性黑色素瘤
  • 鱗狀細胞癌

第14章：肛門癌市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章：肛門癌市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章：肛門癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 肛門癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國：肛門癌市場

第19章 中國：肛門癌市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Accuray Incorporated
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cardinal Health, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Elekta AB
  • Eli Lilly and Company
  • Fresenius Kabi AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • IBA Worldwide
  • McKesson Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • ViewRay Technologies, Inc.
Product Code: MRR-CD5A9334D00D

The Anal Cancer Market was valued at USD 1.13 billion in 2025 and is projected to grow to USD 1.20 billion in 2026, with a CAGR of 6.59%, reaching USD 1.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.13 billion
Estimated Year [2026] USD 1.20 billion
Forecast Year [2032] USD 1.77 billion
CAGR (%) 6.59%

A clear and authoritative orientation to recent clinical advances, evolving care pathways, and strategic priorities shaping anal cancer practice and research

Anal cancer has evolved from a relatively specialized clinical concern to a focal point of multidisciplinary research, owing to advances in immuno-oncology, precision diagnostics, and refinements in multimodal therapy. Over recent years, treatment algorithms have become more nuanced as clinicians balance local control with organ preservation, and as systemic options expand beyond conventional cytotoxic agents. Consequently, stakeholders across clinical practice, clinical development, and health policy require concise synthesis of therapeutic developments, diagnostic innovations, and service delivery changes that influence patient outcomes and resource allocation.

This executive summary distills the core trends shaping clinical practice and commercial strategy for anal cancer, contextualizing therapeutic innovations alongside care pathway shifts and regional practice variation. It highlights the interplay between established modalities such as chemoradiotherapy and surgery and emergent classes like checkpoint inhibitors and targeted approaches. Moreover, it frames how diagnostic refinements and administration modes influence treatment selection and patient experience. The goal is to equip decision-makers with a clear, actionable perspective that supports clinical program planning, vendor assessment, and research prioritization.

How molecular diagnostics, immunotherapy integration, and care delivery redesign are reshaping treatment pathways and commercial strategies in anal cancer

The landscape of anal cancer care is undergoing transformative shifts driven by molecular insights, therapeutic innovation, and a renewed emphasis on patient-centric delivery models. Immunotherapy has moved from investigational promise toward broader integration in certain patient cohorts, prompting re-evaluation of sequencing and combination strategies relative to established chemoradiotherapy approaches. Concurrently, improvements in radiotherapy technology and planning are enabling more precise dose delivery, which reduces toxicity and supports organ preservation, thereby influencing surgical referral patterns.

In parallel, diagnostic capabilities have improved, with molecular profiling and advanced pathology techniques clarifying histologic subtypes and potential actionable targets. These diagnostics are precipitating a shift from one-size-fits-all protocols toward more tailored regimens informed by tumor biology and patient factors. Additionally, the care landscape is becoming more distributed: oncology centers, ambulatory surgical centers, and specialty clinics are sharing responsibilities in ways that enhance access but require new coordination models. Taken together, these shifts demand that clinical leaders and commercial teams rethink trial designs, market access approaches, and provider engagement strategies to remain aligned with the evolving standard of care.

The 2025 tariff environment compelled supply chain resilience, procurement realignment, and adaptive contracting to sustain therapy access and clinical operations

Tariff changes implemented in 2025 across the United States introduced new variables for supply chains, device procurement, and import-dependent therapeutics that are relevant to stakeholders involved in anal cancer care. In the short term, procurement teams and hospital pharmacies have faced adjustments in sourcing decisions as import costs for certain specialized equipment and reagents rose, prompting shifts toward domestic suppliers where available and accelerated negotiations with alternate vendors. This environment has also underscored the importance of resilient supply chain planning for radiotherapy components, diagnostic kits, and parenteral therapies that are sensitive to cross-border logistics.

Over the medium term, manufacturers and distributors have responded by diversifying manufacturing footprints and reviewing pricing strategies to mitigate tariff-driven cost pressure. Payer and provider contract negotiations increasingly factor in these input-cost dynamics, affecting formulary placement discussions and purchasing cycles. For clinical trial operations, tariff-related supply chain constraints have necessitated contingency planning to ensure continuity of investigational drug supply and equipment availability at participating sites. Overall, the 2025 tariff environment emphasized the need for strategic sourcing, flexible contracting, and proactive stakeholder communication to protect treatment continuity and clinical development timelines.

Detailed segmentation-driven perspectives revealing how therapeutic modalities, care settings, and delivery channels shape clinical decision-making and commercial positioning

Segmentation analysis reveals how treatment choices, care settings, therapeutic lines, disease staging, administration modes, cancer histology, and distribution channels create distinct decision-making pathways for stakeholders. Across treatment types, conventional chemotherapy remains foundational, with single-agent and combination regimens applied in defined clinical contexts, while combined modality approaches such as concurrent and sequential chemoradiotherapy are central to balancing tumor control with functional outcomes. Surgical options span abdominoperineal resection and local excision, with selection guided by tumor extent, patient preference, and salvage considerations. Immunotherapy, delineated by checkpoint inhibitors and vaccine strategies, and targeted approaches such as EGFR inhibitors, are influencing late-line strategies and trial design.

End users shape uptake and delivery models: ambulatory surgical centers and specialty clinics often facilitate minimally invasive procedures and follow-up care, while diagnostic laboratories, both molecular and traditional pathology services, underpin treatment personalization and staging decisions. Hospitals, including community and tertiary settings, remain pivotal for complex multimodality care and inpatient management. Therapeutic line segmentation highlights different clinical priorities across first-line approaches that combine chemoradiotherapy and radiotherapy alone, second-line choices where chemotherapy, immunotherapy, and targeted therapies compete, and later-line pathways that often rely on clinical trials and palliative strategies. Disease stage stratification into early and advanced categories determines aggressiveness of local therapy and systemic options. Administration mode distinctions-intravenous, oral, topical-affect patient convenience, adherence considerations, and care setting logistics. Histologic subtypes such as adenocarcinoma, melanoma-related presentations, and squamous cell carcinoma present unique biological behaviors that influence both diagnostic workflows and therapeutic targeting. Finally, distribution channels spanning hospital, online, and retail pharmacy networks shape access, dispensing practices, and patient support services. Integrating these segmentation lenses enables more granular product positioning, clinical trial cohort definition, and value communication tailored to distinct stakeholder needs.

A comparative regional analysis of practice patterns, regulatory landscapes, and access considerations shaping anal cancer care across global markets

Regional dynamics influence clinical practice patterns, reimbursement norms, and trial ecosystems in meaningful ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated oncology networks and established clinical trial infrastructures facilitate rapid adoption of practice-changing evidence and support complex multimodality care, while payer diversity necessitates nuanced access strategies that account for public and private reimbursement mechanisms. Transitioning to value-based discussions is underway in many centers, which alters formulary negotiation and patient management priorities.

Across Europe, Middle East & Africa, regulatory environments and health system organization vary substantially, driving heterogeneity in access to advanced diagnostics and novel therapies. In Western European systems, centralized HTA assessments and multidisciplinary tumor boards often accelerate evidence translation, whereas resource constraints in other parts of the region lead to more conservative adoption patterns and reliance on surgical or radiotherapy-centered approaches. The Asia-Pacific region presents a mix of high-capacity tertiary centers and rapidly expanding oncology services, with strong interest in localized manufacturing and regional clinical development partnerships. Variations in disease epidemiology, patient demographics, and care delivery infrastructures across these regions shape clinical trial enrollment strategies, real-world evidence generation priorities, and commercialization roadmaps. Appreciating and planning for these regional nuances is essential for effective stakeholder engagement and sustainable program implementation.

How collaboration among clinical centers, diagnostics innovators, and commercial partners is accelerating therapeutic development and market entry in anal cancer

The competitive and collaborative landscape includes biopharmaceutical innovators, diagnostics developers, contract research organizations, and specialized device manufacturers focused on therapeutic delivery and radiation planning. Leading clinical investigators and academic centers continue to drive evidence generation through investigator-initiated studies and multicenter trials that evaluate combination regimens, novel immunotherapies, and biomarker-driven approaches. Diagnostic providers are enhancing molecular and pathology workflows to better characterize tumor biology, which supports more selective patient enrollment and companion diagnostic strategies.

Commercial actors are increasingly partnering across the value chain to accelerate clinical development and market entry, combining clinical expertise with distribution networks and payer engagement capabilities. Smaller companies with niche technologies are attractive partners for larger firms seeking to expand portfolios or fill therapeutic gaps. Additionally, service providers that offer trial operations, real-world evidence collection, and health economics expertise are gaining prominence as sponsors seek to demonstrate value and support reimbursement submissions. These dynamics indicate a collaborative ecosystem where strategic alliances, licensing agreements, and co-development models will play a central role in advancing therapeutic options and improving patient outcomes.

Actionable strategies for industry leaders to align clinical development, payer engagement, and supply chain resilience for sustained commercial success in anal cancer

Industry leaders can sharpen competitive advantage by aligning clinical development with emerging standards of care and by investing in data strategies that demonstrate real-world effectiveness and value. Prioritizing late-stage translational research that links biomarker-defined populations to therapeutic outcomes will improve trial efficiency and market differentiation. Moreover, aligning commercial readiness plans with payer evidence requirements and provider workflow considerations will reduce barriers at launch and support sustainable uptake.

Operationally, building resilient supply chains and flexible manufacturing partnerships will mitigate external shocks and tariff-related uncertainties. Engaging early with multidisciplinary clinical stakeholders and patient advocacy groups will surface unmet needs and inform pragmatic trial endpoints that resonate with both clinicians and payers. Finally, offering comprehensive support services-such as adherence programs, diagnostic enablement, and educational initiatives for providers-will strengthen value propositions and foster long-term adoption of new therapies.

A transparent, multi-source research approach combining clinical evidence appraisal, expert interviews, and stakeholder triangulation to derive actionable strategic insights

The research methodology underpinning this analysis synthesizes peer-reviewed clinical literature, regulatory guidance, expert clinician interviews, and qualitative inputs from payer and provider stakeholders to construct an integrated view of therapeutic, diagnostic, and delivery trends. Data triangulation ensures that clinical assertions are grounded in validated sources, while expert consultations provide context on practice variability and operational considerations. Where appropriate, comparative analyses of treatment pathways and stakeholder incentives were conducted to surface practical implications for product development and commercialization.

Attention was paid to methodological transparency: inclusion criteria for literature, selection rationale for expert informants, and the approach to regional comparison were documented to support reproducibility. Bias mitigation strategies included cross-referencing multiple sources, soliciting divergent expert perspectives, and treating emerging signals with appropriate caveats until corroborated. The resulting synthesis emphasizes qualitative insights and actionable interpretation rather than quantitative extrapolation, ensuring conclusions are applicable to strategic decision-making in clinical development and commercial planning.

Synthesizing clinical evolution, diagnostic advances, and operational readiness to guide strategic decision-making and enhance patient-centered outcomes in anal cancer

In conclusion, the anal cancer landscape is maturing into a complex, multidisciplinary arena where therapeutic innovation, diagnostic refinement, and delivery model evolution converge to influence patient outcomes and commercial prospects. Stakeholders must navigate an environment where immunotherapy and targeted approaches are progressively integrated with established chemoradiotherapy regimens, diagnostics increasingly enable patient selection, and regional practice variation shapes access and trial design. Successful programs will be those that anticipate these shifts by aligning clinical development with real-world practice, building evidence that resonates with payers and providers, and ensuring operational readiness across supply chains and distribution channels.

Moving forward, organizations that combine scientific rigor with pragmatic commercialization planning and proactive stakeholder engagement will be best positioned to translate therapeutic advances into meaningful clinical and economic value. Embracing collaborative models and investing in adaptive trial designs and evidence-generation frameworks will accelerate the path from innovation to standard practice, ultimately improving patient outcomes in this challenging disease space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anal Cancer Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Combined Modality Therapy
    • 8.2.1. Concurrent Chemoradiotherapy
    • 8.2.2. Sequential Chemoradiotherapy
  • 8.3. Immunotherapy
    • 8.3.1. Checkpoint Inhibitors
    • 8.3.2. Vaccine Therapy
  • 8.4. Radiotherapy
    • 8.4.1. Brachytherapy
    • 8.4.2. External Beam Radiotherapy
  • 8.5. Surgery
    • 8.5.1. Abdominoperineal Resection
    • 8.5.2. Local Excision

9. Anal Cancer Market, by End User

  • 9.1. Ambulatory Surgical Centers
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals
  • 9.4. Oncology Centers
  • 9.5. Specialty Clinics

10. Anal Cancer Market, by Therapeutic Line

  • 10.1. First-Line
  • 10.2. Second-Line
  • 10.3. Third-Line And Beyond

11. Anal Cancer Market, by Disease Stage

  • 11.1. Stage III
  • 11.2. Stage IV
  • 11.3. Stage I-II

12. Anal Cancer Market, by Administration Mode

  • 12.1. Intravenous
  • 12.2. Oral
  • 12.3. Topical

13. Anal Cancer Market, by Cancer Type

  • 13.1. Adenocarcinoma
  • 13.2. Melanoma
  • 13.3. Squamous Cell Carcinoma

14. Anal Cancer Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Anal Cancer Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Anal Cancer Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Anal Cancer Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Anal Cancer Market

19. China Anal Cancer Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Accuray Incorporated
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca PLC
  • 20.8. Bayer AG
  • 20.9. Bristol-Myers Squibb Company
  • 20.10. Cardinal Health, Inc.
  • 20.11. Dr. Reddy's Laboratories Ltd.
  • 20.12. Elekta AB
  • 20.13. Eli Lilly and Company
  • 20.14. Fresenius Kabi AG
  • 20.15. GlaxoSmithKline PLC
  • 20.16. Hikma Pharmaceuticals PLC
  • 20.17. IBA Worldwide
  • 20.18. McKesson Corporation
  • 20.19. Merck & Co., Inc.
  • 20.20. Novartis AG
  • 20.21. Pfizer Inc.
  • 20.22. Roche Holding AG
  • 20.23. Sanofi S.A.
  • 20.24. Siemens Healthineers AG
  • 20.25. Sun Pharmaceutical Industries Ltd.
  • 20.26. Teva Pharmaceutical Industries Ltd.
  • 20.27. Varian Medical Systems, Inc.
  • 20.28. ViewRay Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANAL CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANAL CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANAL CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANAL CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANAL CANCER MARKET SIZE, BY CONCURRENT CHEMORADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANAL CANCER MARKET SIZE, BY SEQUENTIAL CHEMORADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANAL CANCER MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANAL CANCER MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANAL CANCER MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANAL CANCER MARKET SIZE, BY ABDOMINOPERINEAL RESECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANAL CANCER MARKET SIZE, BY LOCAL EXCISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANAL CANCER MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANAL CANCER MARKET SIZE, BY ONCOLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANAL CANCER MARKET SIZE, BY FIRST-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANAL CANCER MARKET SIZE, BY SECOND-LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANAL CANCER MARKET SIZE, BY THIRD-LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANAL CANCER MARKET SIZE, BY STAGE I-II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANAL CANCER MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANAL CANCER MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANAL CANCER MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANAL CANCER MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANAL CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANAL CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANAL CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS ANAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GCC ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. GCC ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 226. GCC ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. GCC ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. GCC ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 230. GCC ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 232. GCC ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 259. G7 ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 261. G7 ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. G7 ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. G7 ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. G7 ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 266. G7 ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. G7 ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 271. NATO ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. NATO ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 273. NATO ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 274. NATO ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 276. NATO ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. NATO ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 278. NATO ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 279. NATO ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 280. NATO ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL ANAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 289. UNITED STATES ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. UNITED STATES ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 291. UNITED STATES ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 292. UNITED STATES ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 293. UNITED STATES ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. UNITED STATES ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA ANAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA ANAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA ANAL CANCER MARKET SIZE, BY COMBINED MODALITY THERAPY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA ANAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA ANAL CANCER MARKET SIZE, BY RADIOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA ANAL CANCER MARKET SIZE, BY SURGERY, 2018-2032 (USD MILLION)
  • TABLE 301. CHINA ANAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 302. CHINA ANAL CANCER MARKET SIZE, BY THERAPEUTIC LINE, 2018-2032 (USD MILLION)
  • TABLE 303. CHINA ANAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 304. CHINA ANAL CANCER MARKET SIZE, BY ADMINISTRATION MODE, 2018-2032 (USD MILLION)
  • TABLE 305. CHINA ANAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. CHINA ANAL CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)